Merck KGaA abandons Phase III trial for $1.08bn head & neck cancer drug
The company’s decision follows the independent committee's analysis that the trial is unlikely to meet its primary endpoints.
Explore our marketing solutions
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
